Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...
Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate
Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on ...
GAINESVILLE, Fla., May 28, 2020 /PRNewswire/ -- Arranta Bio ("Arranta"), the leading microbiome contract development and manufacturing organization (CDMO), today announced completion of its process ...
Main opportunities include integrating process validation with modern, science-based approaches, utilizing risk-based strategies like QbD, DOE, and PAT, and adhering to global regulatory standards to ...
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...
SEONGDONG-GU, SEOUL, SOUTH KOREA, January 5, 2023 / EINPresswire.com / -- MDimune Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), ...
GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, and ...
In today’s fast-paced biopharmaceutical industry, accelerating microbial process development is critical for moving from gene to GMP with greater speed and efficiency. This webinar will highlight ...
Designing an efficient platform is crucial for any industrial process. This design process is known as process development, and it has become increasingly important in the pharmaceutical industry at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results